In addition, our investigation identified several targeted therapy drugs that displayed efficacy in their target mutated cell lines, including taselisib and alpelisib (PIK3CA inhibitor) in PIK3CA-mutated CRC, and canertinib and dacomitinib (EGFR inhibitors) in EGFR-mutated lung cancer. This evidence concerns the gene PIK3CA and lung cancer.